- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03331445
Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults & Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections
Study Overview
Status
Intervention / Treatment
Detailed Description
Main Study
Primary Objective: Assess the safety of inhaled NO (gNO) in adults & adolescents with NTM, Burkholderia, Aspergillus Lung Infections and Viral Lung (COVID-19) Infections
Safety will be evaluated by unanticipated adverse events in clinical labs (hematology, coagulation, and serum chemistries); in vitals; in inspired concentration of NO, O2 and NO2 delivered to each subject and; in real time methemoglobin and oxygen saturation levels.
Primary Endpoint:
Determine the safety of gNO in the NTM population,
- as confirmed by no unanticipated adverse events
- Absence of a deleterious mean change in FEV1% predicted (absolute) from baseline
Secondary safety Endpoint: Determine the efficacy of inhaled NO in adults with NTM, Burkholderia and Aspergillus Lung Infections
Efficacy will be evaluated by measuring the change in lung function with spirometry (specifically absolute change in FEV1 % predicted) from baseline to Days 5, 12, 19 and 26.
Secondary Efficacy Endpoint Determine the presence of an efficacy signal of gNO in the NTM, Burkholderia and Aspergillus Lung Infections
Efficacy will be assessed by the antimicrobial effect of inhaled NO on the density of NTM species and other microorganisms in sputum. Serial measurements of these microbial colony counts in sputum have been previously used as a measure of antimicrobial activity in other clinical trials of antibiotics in NTM.
• as confirmed by an improvement in pre-treatment bacterial colonization and post-treatment bacterial colonization on Days 19 and 26 as compared to baseline.
Efficacy will be assessed by change in Quality of Life Score.
- as assessed by an improvement in CRISS Score on Day 5, 19 and 26 as compared to baseline measurement;
- as determined by improvement in six-minute walk test with one minute recovery as compared to baseline measurement.
COVID-19 Substudy
Primary Endpoint:
Efficacy will be evaluated by measuring reduction in the incidence of mechanical assistance of BIPAP, CPAP, intubation and mechanical ventilation during the study period.
Secondary Endpoints:
- Proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring mechanical intervention like BIPAP/CPAP, intubation and mechanical ventilation;
- Mortality from all causes during the study period;
- Negative conversion of COVID-19 RT-PCR from upper respiratory tract measured as the proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab;
- Time to clinical recovery defined as the time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air);
- Alleviation of symptoms recorded in the Modified Jackson Cols score with particular definition of cough (defined as mild or absent in a patient reported scale of severity).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V7H2Y4
- Nitric Solutions-Mobile Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
COVID SubStudy Inclusion Criteria
- Capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol;
- Men and Women ≥ 19 years of age unless local laws dictate otherwise;
- English speaking;
- Suspected of exposure to SARS-CoV-2 with fatigue and at least a fever (>37.90 C) or cough or sore throat or a positive swab for SAR-CoV-2 within 5 days of the of enrollment;
- Must be willing to use an adequate form of contraception (or abstinence) from the time of the first dose with the IMP until after the last dose of IMP.
Exclusion Criteria
- Prior Tracheostomy;
- Concomitant treatment involving high flow nasal cannula;
- Any clinical contraindications, as judged by the attending physician;
- Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study;
- Prior COVID-19 infection or a positive swab for SARS-CoV-2 greater than 5 days from enrollment;
- Family members in the same household already on the study;
- Hydroxychloroquine, colchicine and other experimental antiviral medications;
- unwilling to practice a medically acceptable form of contraception from screening to Day 26 (acceptable forms of contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent).
Recruitment on hold for following Criteria during COVID-19 Pandemic
Inclusion Criteria:
- Written informed consent.
Has been previously diagnosed with NTM, Burkholderia spp and Aspergillus spp. or Corona-like viral infection:
- NTM, Burkholderia spp and Aspergillus spp defined as positive culture(s) of at least one species of Mycobacterium avium Complex (MAC) or Mycobacterium abscessus Complex (MABSCor Burkholderia spp and Aspergillus spp) or Corona-like viral infection:
- History of repeatedly positive cultures (2 or more), irregardless of therapy
- Male or female ≥14 years of age.
- Female not pregnant at time of study.
- Has an FEV1 ≥ 30 % of predicted. c. Suspected corona-like viral infection
Oxygen saturation on room air >92% at screening.
a. Able to breathe without supplemental oxygen for 60 minutes
- Non-smoker for at least 6 months prior to screening and agrees not to smoke during the study.
- Willing and able to comply with the treatment schedule and procedures.
Exclusion Criteria:
- Use of an investigational drug within 30 days of screening
- History of frequent epistaxis (>1 episode/month)
- Significant hemoptysis within 30 days (≥ 5 mL of blood in one coughing episode or > 30 mL of blood in a 24 hour period)
- History of reactive pulmonary vascular hypertension
- Methemoglobin >3% at screening
- Liver function insufficiency (ALT/ AST >3 of normal values)
- Hemoglobin <11 g/dl
- Thrombocytopenia (platelet count <100,000/mm3) at screening
- Prothrombin time international ratio (INR) > 1.3 at screening
- Changes to antibiotics (e.g. azithromycin) from 7 days prior to screening through last treatment day. (Subjects may be taking antibiotics or antivirals during this time period, but they cannot start, stop or change doses during this time period)
- On supplemental oxygen during gNO treatment (SaO2 < 90% for 50 minutes while resting in a chair).
For women of child bearing potential:
- positive pregnancy test at screening or
- lactating or
- unwilling to practice a medically acceptable form of contraception from screening to Day 36 (acceptable forms of contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent)
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 160 ppm Nitric Oxide
|
Inhaled Nitric Oxide 160ppm balance air
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects
Time Frame: 26 Days
|
Measure the number of unanticipated adverse events over the duration of the study protocol
|
26 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects
Time Frame: Day 5,12,19 and 26
|
Measure the change in absolute FEV1.0 change from baseline during 160 ppm inhalation therapy
|
Day 5,12,19 and 26
|
Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum
Time Frame: Day 19 and 26
|
Measure the difference from baseline NTM species bacterial load (0 to +4) in sputum during 160ppm nitric oxide inhalation therapy
|
Day 19 and 26
|
Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score
Time Frame: Day 19 and 26
|
Measure the difference from baseline CRISS (0-100) during 160ppm nitric oxide inhalation therapy (lower score represents higher quality of life)
|
Day 19 and 26
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sub-Study Primary Endpoint(s): Efficacy to reduce respiratory interventions
Time Frame: Day 26
|
Measuring reduction in the incidence of mechanical assistance including oxygen therapy, BIPAP, CPAP, intubation and mechanical ventilation during the study period.
|
Day 26
|
Efficacy in reduction of mortality
Time Frame: Day 26
|
Measured by death from all causes
|
Day 26
|
Antiviral effect
Time Frame: Day 26
|
Assessed by time to negative conversion of COVID-19 RT-PCR from upper respiratory tract
|
Day 26
|
Efficacy on clinical improvement
Time Frame: Day 26
|
Time to clinical recovery as measured by resolution of clinical signs
|
Day 26
|
Efficacy on the respiratory symptoms
Time Frame: Day 26
|
Measured by change in the Modified Jackson Cold Score
|
Day 26
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeremy D Road, MD, MD
Publications and helpful links
General Publications
- Deppisch C, Herrmann G, Graepler-Mainka U, Wirtz H, Heyder S, Engel C, Marschal M, Miller CC, Riethmuller J. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study. Infection. 2016 Aug;44(4):513-20. doi: 10.1007/s15010-016-0879-x. Epub 2016 Feb 9.
- Miller C, Miller M, McMullin B, Regev G, Serghides L, Kain K, Road J, Av-Gay Y. A phase I clinical study of inhaled nitric oxide in healthy adults. J Cyst Fibros. 2012 Jul;11(4):324-31. doi: 10.1016/j.jcf.2012.01.003. Epub 2012 Apr 18.
- Yaacoby-Bianu K, Gur M, Toukan Y, Nir V, Hakim F, Geffen Y, Bentur L. Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients. Pediatr Infect Dis J. 2018 Apr;37(4):336-338. doi: 10.1097/INF.0000000000001780.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Disease Attributes
- Coronavirus Infections
- Infections
- Communicable Diseases
- Respiratory Tract Infections
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Antioxidants
- Free Radical Scavengers
- Endothelium-Dependent Relaxing Factors
- Gasotransmitters
- Nitric Oxide
Other Study ID Numbers
- NTM-CTP-01: H17-02107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Tract Infections
-
Vakzine Projekt Management GmbHFGK Clinical Research GmbHUnknownInfection, Respiratory TractGermany
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractGermany
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractAustralia
-
GlaxoSmithKlineCompletedInfections, Respiratory Tract
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusCanada
Clinical Trials on Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation
-
Washington University School of MedicineCompleted
-
MallinckrodtCompletedCystic FibrosisUnited States
-
EpicentreHarvard Medical School (HMS and HSDM); Massachusetts General Hospital; Mbarara... and other collaboratorsCompleted
-
Boston Children's HospitalPraxair Distribution, Inc.WithdrawnAnalgesia | Adolescent Health | Contraceptive Devices | Long-Acting Reversible Contraception | GynecologyUnited States
-
Xijing HospitalMassachusetts General Hospital; Fondazione IRCCS Ca' Granda, Ospedale Maggiore...WithdrawnSARS (Severe Acute Respiratory Syndrome) | Coronavirus Covid-19 Infection Variant Omicron
-
Roger AlvarezBellerophon TherapeuticsWithdrawn
-
Xijing HospitalRecruitingCOVID-19 | Postoperative Complications | Surgery | Nitric OxideChina
-
University of ChicagoThe AlfredRecruitingMajor Depressive Disorder | Treatment Resistant DepressionUnited States, Australia
-
University of ChicagoRecruiting
-
University of ChicagoNot yet recruitingSuicidal Ideation | Major Depressive Disorder | Treatment Resistant DepressionUnited States